Osteochondral Defects (OCDs) and Stem Cells

Gout,Pain,Syndrome,Concept.,Doctor,Check,Up,Or,Exam,Patient

Osteochondral defects (OCDs) of the talus are a common source of pain and disability in young adults. The majority of OCDs occurs in the weight-bearing portions of the talus, particularly the medial and lateral weight-bearing surfaces. These defects can result in pain, joint instability, and loss of function. OCDs can be caused by a variety of factors, including trauma, overuse, and degenerative changes. Mesenchymal stem cells (MSCs) are a promising treatment option for OCDs because of their ability to differentiate into multiple cell types, including chondrocytes. MSCs can be derived from a variety of sources, including bone marrow, adipose tissue, and umbilical cord tissue. There are a number of clinical trials underway evaluating the efficacy of MSCs in the treatment of OCDs. Early results are promising, with patients reporting decreased pain and improved function. However, more research is needed to determine the long-term efficacy of MSCs in the treatment of OCDs.

 "Using Stem Cell Therapy To Treat Osteochondral Defect Of The Knee." 5 Apr. 2020, https://cellaxys.com/using-stem-cell-therapy-to-treat-osteochondral-defect-of-the-knee/. Accessed 21 Oct. 2022.

 "The effect of autologous adipose-derived mesenchymal stem cell ...." 14 Jul. 2017, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513163/. Accessed 21 Oct. 2022.

 "Stem cell transplantation for the treatment of osteochondral defects ...." https://www.syngenit.com/app/download/5816282824/The+Knee_Publication_Syngenit+Surgical%5B843%5D.pdf. Accessed 21 Oct. 2022.

The information below is the recommended stem cell therapy protocol for this condition 

Route of AdministrationDoseTime (Days)Total Cells
IV50,000,0003150,000,000
Myers cocktail/NAD50,000,0001N/A
Intra-articular50,000,000150,000,000
Total200,000,000